AMENDMENT NO. 2 TO THE SALES AGREEMENTThe Sales Agreement • May 10th, 2023 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances)
This Amendment No. 2 to the sales agreement (this “Amendment No. 2”) is entered into as of the date first written above by Beam Therapeutics Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are parties to that certain sales agreement, dated April 1, 2021 (the “Original Agreement”), as amended by Amendment No. 1 to the Original Agreement, dated July 7, 2021 (“Amendment No. 1” and together with the Original Agreement, the “Sales Agreement”) relating to the offering of up to $800,000,000 of the Company’s Common Shares (as defined below).
UNITY BIOTECHNOLOGY, INC. Shares of Common Stock ($0.0001 par value) AMENDMENT NO. 1 TO THE SALES AGREEMENTThe Sales Agreement • August 19th, 2022 • Unity Biotechnology, Inc. • Pharmaceutical preparations • New York
Reference is made to the Sales Agreement, dated March 15, 2022 (the “Agreement”), by and between Unity Biotechnology, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (the “Agent”). The Company and the Agent (collectively, the “Parties”) wish to amend the Agreement, pursuant to Section 15 of the Agreement, to reduce the aggregate offering price under the Agreement (this “Amendment”). The Parties therefore hereby agree as follows:
AMENDMENT NO. 1 TO THE SALES AGREEMENTThe Sales Agreement • August 16th, 2021 • Solid Biosciences Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of the date first written above by Solid Biosciences Inc., a Delaware corporation (the “Company”), and Jefferies LLC (“Agent”), that are parties to that certain Sales Agreement, dated March 13, 2019 (the “Original Agreement”) relating to the offering of up to $50,000,000 of the Company’s Common Shares (as defined below).
AMENDMENT NO. 1 TO THE SALES AGREEMENTThe Sales Agreement • December 5th, 2023 • Disc Medicine, Inc. • Pharmaceutical preparations
This Amendment No. 1 to the sales agreement (this “Amendment No. 1”) is entered into as of the date first written above by Disc Medicine, Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are parties to that certain sales agreement, dated October 10, 2023 (the “Sales Agreement”) relating to the offering of up to $59,700,000 of the Company’s Common Shares (the “Original Offering Amount”). All capitalized terms not defined herein shall have the meanings ascribed to them in the Sales Agreement.
AMENDMENT NO. 1 TO THE SALES AGREEMENTThe Sales Agreement • March 4th, 2024 • Revolution Medicines, Inc. • Biological products, (no disgnostic substances)
This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of the date first written above by Revolution Medicines, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“TD Cowen”), that are parties to that certain Sales Agreement, dated November 10, 2021 (the “Original Agreement”) relating to the offering of up to $250,000,000 of Shares.
AMENDMENT NO. 1 TO THE SALES AGREEMENTThe Sales Agreement • March 1st, 2021 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Atara Biotherapeutics, Inc., a Delaware corporation (the “Company”), and Cowen and Company, LLC (“Cowen”), are parties to that certain Sales Agreement dated February 27, 2020 (the “Sales Agreement”). All capitalized terms not defined in this Amendment No. 1 to the Sales Agreement (this “Amendment”) shall have the meanings ascribed to them in the Sales Agreement. The parties, intending to be legally bound, hereby amend the Sales Agreement as follows (to be effective as set forth in paragraph 4 below):
AMENDMENT NO. 1 TO THE SALES AGREEMENTThe Sales Agreement • July 7th, 2021 • Beam Therapeutics Inc. • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to the Sales Agreement (this “Amendment”) is entered into as of the date first written above by Beam Therapeutics Inc., a Delaware corporation (the “Company”), and Jefferies LLC (the “Agent”), that are parties to that certain Sales Agreement, dated April 1, 2021 (the “Original Agreement”) relating to the offering of up to $300,000,000 of the Company’s Common Shares (as defined below).
